Baird Financial Group
AVXL icon

Baird Financial Group’s Anavex Life Sciences AVXL Stock Holding History

Baird Financial Group’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.2K Buy
+15,528
New +$45.9K ﹤0.01% 1918

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Baird Financial Group's AVXL Position: Q2 2026 in Review

Baird Financial Group opened a new position in Anavex Life Sciences (AVXL) in Q2 2026: 15,528 shares worth $40.2K. The stake represents ﹤0.01% of the portfolio and ranks #1918 among its holdings.

179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Baird Financial Group held 15,528 shares of Anavex Life Sciences worth $40.2K as of Q2 2026.
  • Anavex Life Sciences was a new Baird Financial Group position in Q2 2026.
  • Anavex Life Sciences made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #1918 holding.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.